juna.ai | $7,500,000 | (Nov 21, 2024)
Distru | $6,000,000 | (Nov 21, 2024)
CellPoint Digital | $30,000,000 | (Nov 21, 2024)
Alpha-9 Oncology
United States
- Boston, Massachusetts
- 24/10/2024
- Series C
- $175,000,000
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.
- Industry Biotechnology Research
- Website https://www.a9oncology.com/
- LinkedIn https://www.linkedin.com/company/a9oncology/
Four Growers, Inc. | $9,000,000 | (Nov 21, 2024)
Flywl | $7,000,000 | (Nov 21, 2024)
StoreCash | $3,700,000 | (Nov 21, 2024)
Magma Math | $40,000,000 | (Nov 21, 2024)
Prompt Security | $18,000,000 | (Nov 21, 2024)
Qminder | $3,164,550 | (Nov 21, 2024)
Konsileo | $10,122,225 | (Nov 21, 2024)
BrightAI | $15,000,000 | (Nov 21, 2024)
Valora Therapeutics, Inc. | $30,000,000 | (Nov 21, 2024)